Eton Pharmaceutcials

ETON

Market cap $448M

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in NYC as follows: DATE: Thursday, December 4, 2025 TIME: 9:30AM ETLOCATION: Lotte New York Palace To schedule a 1x1 meeting with the Company, please contact your Piper Sandler institutional sales representative.

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY.

Eton Pharmaceuticals, Inc. ( ETON ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - President, CEO & Director James Gruber - CFO, Treasurer & Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Swayampakula Ramakanth - H.C.

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.02 per share a year ago.

Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 million ET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026 GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patients Held positive FDA meeting clarifying pathway to KHINDIVI™ label expansion Submitted proposed clinical study to support INCRELEX® label expansion Generated $12.0 million of cash from operations in the quarter Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2025.

DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025.

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to fair value ($26.17) in the base case, with even higher potential in optimistic scenarios. Risks include pipeline failures and US drug price pressures, but even pessimistic scenarios suggest current valuation is fair, limiting downside.

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.